SG Americas Securities LLC Takes Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 15,563 shares of the company’s stock, valued at approximately $78,000.

Several other large investors also recently bought and sold shares of the business. The Manufacturers Life Insurance Company purchased a new stake in TScan Therapeutics during the 2nd quarter valued at $90,000. Troluce Capital Advisors LLC bought a new stake in shares of TScan Therapeutics in the second quarter worth $543,000. Great Point Partners LLC purchased a new stake in TScan Therapeutics during the second quarter valued at $5,504,000. Marshall Wace LLP lifted its holdings in TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after acquiring an additional 116,316 shares during the period. Finally, Bank of Montreal Can purchased a new position in TScan Therapeutics in the second quarter worth about $749,000. 82.83% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the transaction, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was bought at an average cost of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at approximately $238,050. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired 15,000 shares of company stock worth $82,550 in the last three months. 2.76% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research note on Monday, August 12th. Finally, Wedbush restated an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, TScan Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Up 0.6 %

TCRX opened at $4.89 on Tuesday. The stock has a market cap of $259.02 million, a price-to-earnings ratio of -4.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. The firm’s fifty day moving average is $5.44 and its 200 day moving average is $6.68. TScan Therapeutics, Inc. has a fifty-two week low of $3.40 and a fifty-two week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The business had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. On average, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.17 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.